A dendritic metagene that predicts prognosis and endocrine resistance in breast cancer.
Giampaolo B, Pusztai L, Qi Y, Iwamoto T, Kelly C, Zambetti M, Symmans W, Gianni L. A dendritic metagene that predicts prognosis and endocrine resistance in breast cancer. Journal Of Clinical Oncology 2012, 30: 545-545. DOI: 10.1200/jco.2012.30.15_suppl.545.Peer-Reviewed Original ResearchHazard ratioEndocrine resistanceBreast cancerNeoadjuvant endocrine therapyProliferative breast cancersAdjuvant tamoxifenEndocrine therapyDistant relapseFree survivalUntreated patientsBetter prognosisDendritic cellsEarly relapseOncotype DXPoor prognosisClinical variablesPoor responseUntreated tumorsLower riskMetagene signaturePredictive valueMultivariate analysisTumorsRelapsePrognosis